Saybrook Capital’s Royalty Pharma RPRX Stock Holding History

Saybrook Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,000	Closed	-$273K	–	48
2024 Q1	$273K	Sell	9,000 -8,675	-49%	-$256K	0.07%	45
2023 Q4	$496K	Buy	+17,675	New	+$486K	0.14%	36

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Saybrook Capital's RPRX Position: Q2 2024 in Review

Saybrook Capital sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 9,000 shares — an estimated $273K sold.

Saybrook Capital first reported a position in RPRX in Q4 2023 and held it in 2 quarters. The position peaked at $496K in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

Saybrook Capital reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
Saybrook Capital sold 9,000 Royalty Pharma shares in Q2 2024, an estimated $273K.
Saybrook Capital first reported a position in Royalty Pharma in Q4 2023 and held it in 2 quarters.
Saybrook Capital's Royalty Pharma position peaked at $496K in Q4 2023.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Saybrook Capital's 13F filing for Q2 2024, filed 7 Aug 2024.